12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Hillstream BioPharma (NASDAQ:HILS) stock rose 95.2% to $1.31 during Tuesday’s regular session. As of 12:30 EST, Hillstream…
S&P 500 Down 1%; Crude Oil Drops Over 2%
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 175 points on Monday.
The Dow traded down 0.59% to 33,777.39 while the NASDAQ fell 1.58% to 11,438.31. The S&P 500 also fell, dropping, 1.03% to 4,028.82.
Dow Drops 75 Points; G Medical Innovations Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday.
The Dow traded down 0.23% to 33,901.34 while the NASDAQ fell 1.25% to 11,476.46. The S&P 500 also fell, dropping, 0.68% to 4,043.02.
US Stocks Open Lower; Nasdaq Down 1%
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday.
Following the market opening Monday, the Dow traded down 0.14% to 33,931.09 while the NASDAQ fell 1% to 11,504.93. The S&P 500 also fell, dropping, 0.54% to 4,048.50.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 7026.4% to $6.04 during Monday’s pre-market session. The market value…
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+ program members.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday’s pre-market session. The market value of their…
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket
Gainers
VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo patient was dosed in Phase 1a/b clinical trial of novel BET inhibitor VYN201.
